BRISTOL MYERS SQUIBB

Cell therapy, particularly CAR-T, is advancing in treating autoimmune diseases, showing promise in early trials for conditions like lupus. Despite no approvals yet, its potential for curative effects excites the field. Companies like Kyverna, Cabaletta, and Cartesian are leading research, with some patients experiencing life-changing results. However, experts caution about overhyping, emphasizing the need for long-term data and recognizing that cell therapy won't work for all patients.

The Eosinophilic Esophagitis (EoE) market, valued at ~USD 940 thousand million in 2023, is expected to grow significantly by 2034. EoE, a chronic inflammatory condition, affects 1 in 2,000 people, with the US having the highest cases. Treatments include DUPIXENT and JORVEZA, with ongoing research for better therapies.

Durvalumab showed superior progression-free survival (PFS) vs placebo in unresectable stage III NSCLC patients post-chemoradiotherapy, with a median PFS of 14.0 vs 6.5 months. A trend toward improved overall survival was also noted. PACIFIC-5 supports durvalumab post-CRT, aligning with prior evidence.

Clinical trials often lack diversity, with Black participants representing only 7.3% of enrollees despite being 14.9% of the U.S. population. Decentralized Clinical Trials (DCT) show promise in improving diversity, with certain elements like local labs boosting Black enrollment. Regulatory push and industry backing are increasing, aiming for more inclusive trials. The PACT Consortium, supported by major pharmaceutical companies, is leading efforts to enhance diversity and equity in clinical research.

The FDA approved Opdivo Qvantig for subcutaneous use in adult solid tumor treatments, based on the CheckMate-67T trial showing its noninferiority and higher response rate compared to intravenous Opdivo. This new option offers faster delivery for cancer patients.

The global pharmacy market is projected to grow from US$ 1,161 Billion in 2023 to US$ 1,750 Billion by 2032, at a CAGR of 4.8%. Driven by an aging population, chronic diseases, and technological advancements, the sector is evolving with digital health solutions, online pharmacies, and personalized medicine. Despite challenges like regulatory hurdles and R&D costs, opportunities in digitalization and preventive care are significant.

The phase III SWOG S1815 trial found nab-paclitaxel plus gemcitabine/cisplatin (GAP) did not significantly improve overall survival over gemcitabine/cisplatin alone in advanced biliary tract cancers. GAP showed more toxicity. Median overall survival was 14.0 vs 13.6 months, with no significant difference in progression-free survival.

Studies show non-transplant salvage therapy for low-risk relapsed/refractory pediatric Hodgkin lymphoma achieves high progression-free and overall survival rates, comparable to autologous stem cell transplant. PET-guided therapy offers excellent outcomes, suggesting ASCT may be reserved for higher-risk patients.

In 2024, the ISS National Lab launched 110 payloads across seven missions, advancing biotechnology, materials science, and in-space manufacturing. Key projects included 3D printing of tissues, pharmaceutical research, and optical fiber production. The year also saw validation of new technologies and STEM education initiatives, highlighting the ISS's role in innovation and research.

The Eosinophilic Esophagitis (EoE) market, valued at ~USD 940 thousand million in 2023, is expected to grow significantly by 2034. Key developments include FDA approval of DUPIXENT for pediatric EoE treatment. The 7MM reported ~800,000 EoE cases in 2023, with the US leading. Treatments involve dietary changes, medications like PPIs, and emerging therapies.